UroGen Pharma Ownership | Who Owns UroGen Pharma?
UroGen Pharma Ownership Summary
UroGen Pharma is owned by 87.89% institutional investors, 6.79% insiders, and 5.32% retail investors. Rtw investments, lp is the largest institutional shareholder, holding 9.52% of URGN shares. BioPharma Credit Ord is the top mutual fund, with 10.18% of its assets in UroGen Pharma shares.
URGN Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | UroGen Pharma | 87.89% | 6.79% | 5.32% |
| Sector | Healthcare Stocks | 42.54% | 10.83% | 46.63% |
| Industry | Biotech Stocks | 45.22% | 10.75% | 44.04% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Rtw investments, lp | 4.54M | 9.52% | $90.65M |
| Paradigm biocapital advisors lp | 4.22M | 8.83% | $84.11M |
| Toronto dominion bank | 3.19M | 6.68% | $63.65M |
| Blackrock | 2.19M | 6.57% | $36.81M |
| Cowen and company | 2.10M | 6.29% | $35.23M |
| Blackrock funding, inc. /de | 2.58M | 5.41% | $51.50M |
| Morgan stanley | 2.53M | 5.30% | $50.44M |
| Jefferies financial group | 2.20M | 4.61% | $43.88B |
| Silverarc capital management | 1.58M | 3.30% | $31.47M |
| Acorn capital advisors | 1.26M | 2.64% | $25.13M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Acorn capital advisors | 1.26M | 12.76% | $25.13M |
| Silverarc capital management | 1.58M | 4.24% | $31.47M |
| Boxer capital management | 575.00K | 3.66% | $11.47M |
| Paradigm biocapital advisors lp | 4.22M | 2.39% | $84.11M |
| Superstring capital management lp | 87.91K | 1.73% | $1.75M |
| Rtw investments, lp | 4.54M | 1.12% | $90.65M |
| Cowen and company | 2.10M | 0.97% | $35.23M |
| Parkman healthcare partners | 402.60K | 0.84% | $8.03M |
| Tang capital management | 1.00M | 0.77% | $19.95M |
| Privium fund management b.v. | 196.62K | 0.71% | $3.92M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Paradigm biocapital advisors lp | 4.22M | 2.39% | 4.22M |
| Tcg crossover management | 717.35K | 0.70% | 717.35K |
| Voloridge investment management | 687.48K | 0.05% | 687.48K |
| Blackrock | 2.19M | 0.00% | 477.14K |
| Cowen and company | 2.10M | 0.97% | 472.89K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Ubs asset management americas | - | - | -4.36M |
| Ra capital management | - | - | -3.21M |
| Vestal point capital, lp | - | - | -2.15M |
| Soleus capital management | 679.00K | 0.68% | -1.51M |
| Millennium management | 645.78K | 0.00% | -853.42K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Paradigm biocapital advisors lp | 4.22M | 2.39% | 4.22M | $84.11M |
| Tcg crossover management | 717.35K | 0.70% | 717.35K | $14.31M |
| Voloridge investment management | 687.48K | 0.05% | 687.48K | $13.72M |
| Bioimpact capital | 135.00K | 0.44% | 135.00K | $2.69M |
| Two sigma advisers, lp | 111.60K | 0.00% | 111.60K | $2.23M |
Sold Out
| Holder | Change |
|---|---|
| Twin peaks wealth advisors | -2.00 |
| Nelson, van denburg & campbell wealth management group | -4.00 |
| Ifp advisors | -4.00 |
| Coldstream capital management | -29.00 |
| Us bancorp \de\ | -47.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2025 | 162 | 4.52% | 41,959,889 | 15.94% | 87 | 1.53% | 82 | 2.50% | 45 | 7.14% |
| Jun 30, 2025 | 163 | 13.99% | 39,787,671 | -4.46% | 83 | 1.08% | 84 | 31.25% | 43 | -12.24% |
| Mar 31, 2025 | 143 | 2.14% | 41,643,982 | 14.80% | 87 | 1.24% | 64 | -11.11% | 49 | 25.64% |
| Dec 31, 2024 | 101 | -23.48% | 19,804,522 | -43.62% | 45 | 0.69% | 52 | -30.67% | 26 | -13.33% |
| Sep 30, 2024 | 132 | 9.09% | 35,128,434 | -8.10% | 81 | 0.76% | 75 | -5.06% | 30 | 50.00% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| BioPharma Credit Ord | 4.69M | 10.18% | 4.69M |
| UBS (Lux) Digital Health Equity SB USD | 1.32M | 2.86% | - |
| UBS Lux Dgtl Hlth Eq Fd seeding P acc | 1.25M | 2.71% | - |
| iShares Russell 2000 ETF | 887.92K | 1.92% | - |
| International Biotechnology Ord | 427.15K | 0.93% | -34.85K |
| Fidelity Small Cap Index | 369.83K | 0.80% | -17.56K |
| iShares Russell 2000 Growth ETF | 264.63K | 0.57% | - |
| State St Russell Sm/Mid Cp® Indx NL Cl C | 262.40K | 0.57% | - |
| State St Russell Sm/Mid Cp® Indx SL Cl I | 262.40K | 0.57% | - |
| iShares Biotechnology ETF | 233.34K | 0.50% | - |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Nov 19, 2025 | Schoenberg Mark | Chief Medical Officer | Sell | $250.00K |
| Oct 08, 2025 | Degnan Chris | Chief Financial Officer | Sell | $37.12K |
| Sep 08, 2025 | Schoenberg Mark | Chief Medical Officer | Sell | $16.64K |
| Sep 08, 2025 | Smith Jason Drew | General Counsel | Sell | $29.05K |
| Aug 11, 2025 | Schoenberg Mark | Chief Medical Officer | Sell | $176.90K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q4 | - | 2 |
| 2025 Q3 | - | 5 |
| 2025 Q2 | - | 1 |
| 2025 Q1 | - | 6 |
| 2024 Q4 | - | - |
URGN Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools